NLS Acquisition

AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals has cleared US Federal Trade Commission review. This follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The announcement follows competition clearances in Canada, Brazil, Russia and other countries globally, with a full list available on astrazeneca.com. Additional global regulatory clearances are pending, including but […]

Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT) further strengthening the CTR group with optimized toxicological support. From April 1, TKT is a fully owned subsidiary to the holding company CTR, states the company in a press release. Elinor Hahne will continue as CEO of TKT The activities at […]

PrecisionLife has acquired its long-term Danish technology development partner GenoKey. The acquisition enables PrecisionLife to continue its expansion as an AI-enabled precision medicine company, it states. Financial details of the paper-based transaction were not disclosed. Benefit from GenoKey’s strong relationships with the Danish health system and leading academic clinical research centers PrecisionLife’s platform, which includes […]

Amgen and Five Prime Therapeutics have announced an agreement under which Amgen will acquire Five Prime Therapeutics for USD 38 per share in cash, representing an equity value of approximately USD 1.9 billion. Five Prime’s lead asset, bemarituzumab, is a Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study […]

Oasmia Pharmaceutical has signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. The agreement is the first in a series of planned in-licensing deals and acquisitions to expand Oasmia’s oncology portfolio, leveraging its […]

Xbrane Biopharma has entered into a non-binding term-sheet with NewFaDem for a divestment of Primm Pharma. Xbrane’s long term focus is to become a world leading biosimilar developer, and hence Primm Pharma falls outside its strategic scope, the company states in its press release. A total consideration of up to €14 million The non-binding terms […]